CY1108648T1 - Αναστολεας της αρωματασης σε μια δοση για την θεραπευτικη αντιμετωπιση της υπογόνιμοτήτας - Google Patents

Αναστολεας της αρωματασης σε μια δοση για την θεραπευτικη αντιμετωπιση της υπογόνιμοτήτας

Info

Publication number
CY1108648T1
CY1108648T1 CY20081101446T CY081101446T CY1108648T1 CY 1108648 T1 CY1108648 T1 CY 1108648T1 CY 20081101446 T CY20081101446 T CY 20081101446T CY 081101446 T CY081101446 T CY 081101446T CY 1108648 T1 CY1108648 T1 CY 1108648T1
Authority
CY
Cyprus
Prior art keywords
woman
fsh
aromatase inhibitor
inhibitor
medicament
Prior art date
Application number
CY20081101446T
Other languages
Greek (el)
English (en)
Inventor
Robert F Casper
Mohamed F M Mitwally
Original Assignee
Ares Trading S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ares Trading S.A. filed Critical Ares Trading S.A.
Publication of CY1108648T1 publication Critical patent/CY1108648T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/30—Oestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CY20081101446T 2001-04-17 2008-12-12 Αναστολεας της αρωματασης σε μια δοση για την θεραπευτικη αντιμετωπιση της υπογόνιμοτήτας CY1108648T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US28428201P 2001-04-17 2001-04-17
EP02717919A EP1383578B1 (en) 2001-04-17 2002-04-17 Single dose aromatase inhibitor for treating infertility

Publications (1)

Publication Number Publication Date
CY1108648T1 true CY1108648T1 (el) 2014-04-09

Family

ID=23089583

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20081101446T CY1108648T1 (el) 2001-04-17 2008-12-12 Αναστολεας της αρωματασης σε μια δοση για την θεραπευτικη αντιμετωπιση της υπογόνιμοτήτας

Country Status (32)

Country Link
US (1) US8008333B2 (enExample)
EP (1) EP1383578B1 (enExample)
JP (1) JP2004529924A (enExample)
KR (1) KR20040025916A (enExample)
CN (1) CN1551789A (enExample)
AR (1) AR034036A1 (enExample)
AT (1) ATE409066T1 (enExample)
AU (1) AU2002249043B2 (enExample)
BG (1) BG108323A (enExample)
BR (1) BR0208920A (enExample)
CA (1) CA2444980C (enExample)
CY (1) CY1108648T1 (enExample)
CZ (1) CZ20033107A3 (enExample)
DE (1) DE60229047D1 (enExample)
DK (1) DK1383578T3 (enExample)
EA (1) EA011310B1 (enExample)
EE (1) EE200300505A (enExample)
ES (1) ES2311599T3 (enExample)
HR (1) HRP20030839A2 (enExample)
HU (1) HUP0304003A2 (enExample)
IL (1) IL158396A0 (enExample)
MX (1) MXPA03009447A (enExample)
NO (1) NO20034246L (enExample)
NZ (1) NZ552873A (enExample)
PL (1) PL366744A1 (enExample)
PT (1) PT1383578E (enExample)
SI (1) SI1383578T1 (enExample)
SK (1) SK14242003A3 (enExample)
UA (1) UA82648C2 (enExample)
WO (1) WO2002083241A1 (enExample)
YU (1) YU81203A (enExample)
ZA (1) ZA200307516B (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003247404A1 (en) * 2002-07-02 2004-01-23 Pharmacia & Upjohn Company Llc Infertility treatment with exemestane
JP2006522151A (ja) 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤
WO2007000056A1 (en) * 2005-06-28 2007-01-04 Casper Robert F Aromatase inhibitors for emergency contraception
US20100280046A1 (en) * 2006-01-10 2010-11-04 Diobex, Inc. Methods and Compositions for Treating Prostate Cancer, Benign Prostatic Hypertrophy, Polycystic Ovary Syndrome and Other Conditions
AU2011256088B2 (en) * 2010-05-20 2015-03-26 University Of Saskatchewan Use of aromatase inhibitors for synchronizing ovulation, inducing superovulation or double ovulation and improving twinning and fertility in a mammal
US10004723B2 (en) 2013-04-19 2018-06-26 University Of Saskatchewan Aromatase inhibitor-releasing intravaginal device
US20160022644A1 (en) * 2014-07-22 2016-01-28 Tsu-I Catherine Wang Oral Transmucosal Compositions Including Aromatase Inhibitors for Treating Female Infertility

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4728645A (en) * 1982-12-21 1988-03-01 Ciba-Geigy Corporation Substituted imidazo[1,5-A]pyridine derivatives and other substituted bicyclic derivatives, useful as aromatase inhibitors
US4602025A (en) * 1984-06-18 1986-07-22 Eli Lilly And Company Aromatase inhibitors
US4845227A (en) * 1984-06-18 1989-07-04 Eli Lilly And Company Aromatase inhibitors from azoles
US4978672A (en) * 1986-03-07 1990-12-18 Ciba-Geigy Corporation Alpha-heterocyclc substituted tolunitriles
GB8726505D0 (en) * 1987-11-12 1987-12-16 Ici Plc Naphtho(2 1-b)furan derivatives
DE4330237C2 (de) 1993-09-02 1995-11-30 Schering Ag 1-Methylsubstituierte Androsta-1,4-dien-3,17-dione, Verfahren zu deren Herstellung und diese enthaltende pharmazeutische Präparate
AU2407997A (en) * 1996-04-30 1997-11-19 Takeda Chemical Industries Ltd. Combined use of gnrh agonist and antagonist
DE19622457A1 (de) 1996-05-24 1997-11-27 Schering Ag 7alpha-(5-Methylaminopentyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha-(5-Methylaminopentyl)-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
US6953774B2 (en) * 2000-08-11 2005-10-11 Applied Research Systems Ars Holding N.V. Methods of inducing ovulation

Also Published As

Publication number Publication date
WO2002083241A1 (en) 2002-10-24
MXPA03009447A (es) 2004-05-24
NO20034246L (no) 2003-12-15
DE60229047D1 (de) 2008-11-06
HUP0304003A2 (hu) 2004-04-28
US20040171660A1 (en) 2004-09-02
SI1383578T1 (sl) 2008-12-31
ES2311599T3 (es) 2009-02-16
CN1551789A (zh) 2004-12-01
IL158396A0 (en) 2004-05-12
DK1383578T3 (da) 2008-11-03
SK14242003A3 (sk) 2004-03-02
BG108323A (bg) 2004-12-30
NO20034246D0 (no) 2003-09-23
CA2444980C (en) 2010-08-17
US8008333B2 (en) 2011-08-30
PL366744A1 (en) 2005-02-07
ATE409066T1 (de) 2008-10-15
EA011310B1 (ru) 2009-02-27
JP2004529924A (ja) 2004-09-30
BR0208920A (pt) 2004-04-20
YU81203A (sh) 2006-05-25
KR20040025916A (ko) 2004-03-26
NZ552873A (en) 2008-05-30
EE200300505A (et) 2004-02-16
HRP20030839A2 (en) 2005-08-31
EP1383578A1 (en) 2004-01-28
EP1383578B1 (en) 2008-09-24
PT1383578E (pt) 2008-10-08
CZ20033107A3 (en) 2004-03-17
UA82648C2 (uk) 2008-05-12
EA200301128A1 (ru) 2004-04-29
AU2002249043B2 (en) 2008-01-10
ZA200307516B (en) 2004-09-27
CA2444980A1 (en) 2002-10-24
AR034036A1 (es) 2004-01-21

Similar Documents

Publication Publication Date Title
DE69739165D1 (de) Matrix mit verzögerter freisetzung für hochdosierte unlösliche arzneistoffe
ATE306266T1 (de) Verbesserte verabreichungstechnik für multiple medikamentengaben
NO970309L (no) Anvendelse av en progesteronantagonist og av et gestagen for behandling av endometriose eller Leiomyomata uteri
BR0115392A (pt) Método para o tratamento de uma doença sensìvel a interferona em um animal de sangue quente, método para individualizar as dosagens de uma interferona no tratamento, método para a fabricação de um dispositivo de liberação de efeito terapêutico de longa duração de uma droga ao longo de um perìodo de tempo, e conjunto útil para a ministração de uma quantidade relativamente constante de uma droga
SE8701900D0 (sv) Pulsed drug delivery
ES488168A0 (es) Proceso para la preparacion de tabletas farmaceuticas o medicinales de administracion oral, con liberacion retardada delagente activo, en tabletas en las que la cantidad de libera-cion del agente activo es predeterminada.
CO5011096A1 (es) Medicamentos que contienen antagonistas del receptor 5-ht3 para el tratamiento de la ibs
KR960706344A (ko) 호르몬 피임 및/또는 여드름 치료 수단 및 방법(means and method for hormonal contraception and/or the treatment of acne)
PT100635A (pt) Forma de dosagem farmaceutica para a administracao retardada de um farmaco
ES2087237T3 (es) Progestogeno como unico contraceptivo.
MX173567B (es) Procedimiento para preparar una composicion farmaceutica y composicion farmaceutica para mejorar los sintomas de enfermedad inducida por vih o reducir la transcripcion y proliferacion del vih
ATE292453T1 (de) Antivirale arznei
CY1108021T1 (el) Αναστολη αρωματασης για ενισχυση του ρυθμου εμφυτευσης
FI971742A7 (fi) Kompetitiivisia progesteroniantagonisteja tarpeen sanelemaan raskauden ehkäisyyn naisilla
EA200200801A1 (ru) Применение фолликулостимулирующего гормона (fsh) для лечения бесплодия
AR034036A1 (es) Inhibidor de aromatasa en una dosis unica para tratar la infertilidad
GR1000989B (el) Μεθοδος παρασκευης συνθεσεως για θεραπεια οστεοπορωσης και ορμονικης ανισορροπιας.
JP2004529924A5 (enExample)
MX9304931A (es) Anticonceptivos que contienen antiprogestogenos.
AR042308A1 (es) Medicamento de administracion transdermica y transmucosica con absorcion mejorada de principios activos
CA2472309A1 (en) Multiple dose aromatase inhibitor for treating infertility
HUP9901474A2 (hu) Szekvenciális ösztrogén/progeszteron-antagonista kombináció hormonhelyettesítő terápiához
TR199901958T2 (xx) �nfertiliteye kar�� ve fertiliteyi art�rmak i�in bir ila�.
CY1106388T1 (el) Θepαπεια ηπατιτιδας c με θυμοσινη, ιντepφepονη και ριβαβιρινη
ECSP034606A (es) Uso de antiprogestinas para la induccion de apoptosis en una celula